PUL-042

Phase 2Small molecule

PPulmotect, Inc.

PUL-042 is one of 38 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

COVID-19Phase 2

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1932 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

Activella

PUL-042

2 4

Tricor

JJagotec

Preclinical

1 5

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 6

Olokizumab

UCB

Preclinical

1 7

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 8

Tpa

UUniversity of Florida

Preclinical

1 9

Opaganib

RRedHill Biopharma Limited

Preclinical

1 10

Hymecromone

SStanford University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

COVID-192 trials

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

Completed·PPulmotect, Inc.·Phase 2·NCT04312997·101 enrolled

The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2

Completed·PPulmotect, Inc.·Phase 2·NCT04313023·217 enrolled

Transplant Recipient1 trial

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

Withdrawn·PPulmotect, Inc.·Phase 1·NCT03097796

Single Ascending Dose1 trial

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

Completed·PPulmotect, Inc.·Phase 1·NCT02124278·42 enrolled

Rhinovirus1 trial

The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD

Completed·PPulmotect, Inc.·Phase 2·NCT03794557·20 enrolled

Treatment1 trial

Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)

Completed·PPulmotect, Inc.·Phase 1·NCT02566252·16 enrolled

1 more indication

Influenza1 trial

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

Recruiting·PPulmotect, Inc.·Phase 2·NCT06665100·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PUL-042. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PUL-042 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PUL-042. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pulmotect, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPulmotect, Inc.

PUL-042

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

COVID-192 trials

Transplant Recipient1 trial

Single Ascending Dose1 trial

Rhinovirus1 trial

Treatment1 trial

Influenza1 trial

References

Drug Info

Quick Facts

Related News